Ibandronic Acid

Form: Oral tablet and Intravenous injection

Strength: Tablet: 150 mg; Injection: 3mg/3ml

Reference Brands: Boniva® (US & EU); Bondronat®(EU)

Category: Women's Health

Ibandronic Acid (marketed as Bonviva® in the EU and Boniva® in the US) is a bisphosphonate used for the treatment and prevention of postmenopausal osteoporosis. It works by inhibiting osteoclast-mediated bone resorption, increasing bone mineral density and reducing the risk of vertebral fractures. Available in oral 150 mg monthly tablets and 3 mg quarterly IV injections, Ibandronic Acid offers flexible dosing options to improve patient compliance. It is marketed in both regions by Roche and its affiliates, ensuring consistent quality and regulatory compliance. Ibandronic Acid is widely adopted in B2B pharmaceutical distribution for women’s health across Europe and North America.